Testing and Analysis Clause Samples

Testing and Analysis. Testing and analysis of each Shipment shall be conducted in accordance with the relevant Confirmation.

Testing and Analysis. Provider is not obligated to test or perform quality analyses of Crude Oil received into, stored in or delivered out of any Facility on behalf of Customer unless specifically agreed to by the Parties in writing, and any such testing or analyses, including costs thereof, will be for Customer’s account. In the absence of fraud or manifest error, any quality determination performed by Provider shall be binding on both Parties. Provider is not obligated to accept, and Provider may, without prejudice to any other remedies, reject Customer’s Crude Oil that fails to conform to the applicable quality specifications of Customer.

Testing and Analysis. 2.1. Where applicable, transfer a copy of the validated analytical test method(s) to NORDION. X 2.2. Test product according to NAVIDEA approved specifications, analytical and microbial test methods and procedures. Provide a copy of the Product Release Form (PRF) to NAVIDEA. X 2.3. Conduct sampling in accordance with approved specifications within the batch record. X 2.4. Within two (2) business days inform NAVIDEA QA of and assist in investigating OOS results identified in any testing conducted by NORDION or an independent lab contracted by NORDION and provide documentation relating to such investigation with the batch record applicable to the batch containing the OOS test result. X 2.5. Complete investigations according to the requirements, including timeliness, in the standard operating procedures. Non-conforming product will be placed on QA Hold until such non-conformance is adequately resolved by completing OOS investigations and reviewing planned deviations. X X 2.6. Promptly inform NORDION of and investigate OOS results identified in any testing conducted by a NAVIDEA designated lab. Promptly provide NORDION copies of documentation relating to such investigations for inclusion with the batch record applicable to the batch containing the OOS test result. X Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 2.7. Within two (2) business days notify NORDION of any recall and/or confirmed stability failure (if applicable). X

Testing and Analysis. The extent of our substantive testing will be based on results of our internal control tests. It has been our experience that governmental entities, like the State of Florida and their State Agencies, often have a system of internal controls that, with appropriately designed tests and correlation to account balances, can be used to limit the extent of account balance substantiation testing. Audit sampling will be used only in those situations where it is the most effective method of testing. Before deciding to sample, we will consider all possible approaches and audit techniques. Items where, in our judgment, acceptance of some sampling risk is not justified will be examined 100 percent. These may include unusual items or items for which potential misstatements could individually equal or exceed tolerable error. After identifying individually significant or unusual items, we will decide on the audit approach for the remaining balance of items by considering tolerable error and audit risk. This may include (1) testing a sample of the remaining balance; (2) lowering the previously determined threshold for individually significant items to increase the percent of coverage of the account balance; or (3) applying analytical procedures to the remaining balance. Our workpapers during this phase will clearly document our work as outlined in our audit programs. We will also provide the entity with status reports during the course of the audit fieldwork. As in all phases of the audit, we will be in communication with the entity to determine that all identified issues are resolved in a timely manner. We will also hold a final exit conference with the entity to summarize the results of our fieldwork and review significant findings.

Testing and Analysis. 3.3.1 City agrees to provide a periodic testing and analysis of the biosolids and to make results of such analysis available to the Operator. While City feels that the material has potential value as a soil conditioner or supplement, such representations are based only upon City's best estimate of the current content of the material and upon available literature as to its value as a soil supplement. 3.3.2 City makes no warranties that any particular benefit will result to the Operator's land, or that any particular future increase in crop yields will result. City does, however, on the basis of its periodic analysis and current literature, represent that the biosolids, if lawfully stored and applied, as explained herein, will not normally result in any environmental damage to the Operator's or adjacent property.